Aptamer-Drug Conjugation Targeted Drug Delivery System
CD Bioparticles offers aptamer-drug coupling targeted drug delivery systems. With our many years of experience in the field of aptamer-targeted drug delivery and our advanced technical equipment, we can provide you with the basis for your experimental research in the field of targeted drug delivery by our core technologies in aptamer and drug coupling design.
Service Background
Novel nucleic acid aptamers have been reported and have attracted the interest of many scientists. Due to the simplicity of chemical modifications and off-the-shelf molecular engineering, scientists have developed newly designed aptamers with various therapeutic approaches, aptamer-drug coupling (ApDC), from chemotherapy to phototherapy, gene therapy, and vaccines, ApDC has shown synergistic therapeutic effects in cancer treatment. Active targeting therapy utilizes the ability of the targeting element to specifically recognize diseased tissue.
Aptamer-drug couples combine a selection of less cytotoxic drugs with the aptamer, so ApDC can selectively target and kill disease cells, including cancer cells while reducing side effects. Aptamer-drug couples (ApDC) are a promising targeted drug delivery system where the aptamer can be directly linked to the drug to form nanoscale aptamer-drug conjugates that target the drug directly to the tumour site, reducing toxicity and improving the efficacy of chemotherapy.
Fig. 1 Schematic of aptamer-drug conjugates (ApDCs) as targeted Chemotherapeutics (Yoon S, et al., 2017)
Our Services
CD Bioparticles provides services for the study of aptamer-drug conjugate targeted drug delivery systems. Currently, targeted therapies are at the forefront of modern medical research into numerous clinical diseases. The nucleic acid aptamer acts as a recognition ligand, targeting the site of disease and/or directing the delivery of a therapeutic agent that regulates the biological function of the target biomarker.
We provide research services for the following, including but not limited to, the following, which will be tailored to your experimental protocol.
-
Construction of ApDC using nucleotide analogs
-
ApDC by drug intercalation
-
ApDCs by using chemical linker
ApDC Applications
-
ApDCs are widely used in several cancer treatment strategies including
-
ApDC for chemotherapy
-
ApDC for gene therapy
-
ApDC for radiotherapy
-
ApDC for synergistic chemoradiotherapy
-
ApDC for synergistic photodynamic therapy
-
ApDC for synergistic immunotherapy
Our Strengths
-
Highly Targeted: ApDC have the potential to improve the therapeutic index of conventional chemotherapeutic agents by specifically delivering cytotoxic drugs to cancer cells while protecting normal cells.
-
High Safety: ApDC are at the forefront of nanomedicine developments for the targeted delivery of chemotherapeutic drugs. Aptamer coupling offers significant advantages over drug delivery alone, including better drug stability, lower toxicity, lower immunogenicity and better safety
-
Lower Production Costs: ApDC are non-aggregating, more stable, less toxic, more specific, and easier and more economical to produce.
CD Bioparticles is already experienced in the field of aptamer-drug conjugation targeted drug delivery systems and our scientists are confident that we can provide you with a quality one-stop aptamer-related service to facilitate the development of research in the area of targeted drug delivery. If you are interested in our services, please do not hesitate to contact us for more details and we look forward to hearing from you.
Quotations and Ordering
Reference
-
Yoon S, Huang KW, Reebye V, et al. Aptamer-Drug Conjugates of Active Metabolites of Nucleoside Analogs and Cytotoxic Agents Inhibit Pancreatic Tumor Cell Growth. Mol Ther Nucleic Acids. 2017; 6: 80-88.
